Moderna (MRNA) Preferred Stock Liabilities (2017)

Moderna (MRNA) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $1.2 billion as the latest value for Q4 2017.

For Q4 2017, Preferred Stock Liabilities changed 0.0% year-over-year to $1.2 billion; the TTM value through Dec 2017 reached $1.2 billion, changed 0.0%, while the annual FY2017 figure was $1.2 billion, 0.0% changed from the prior year.
Preferred Stock Liabilities hit $1.2 billion in Q4 2017 for Moderna, roughly flat from $1.2 billion in the prior quarter.
Across five years, Preferred Stock Liabilities topped out at $1.2 billion in Q4 2016 and bottomed at $1.2 billion in Q4 2016.

Peer Comparison